<DOC>
	<DOCNO>NCT00962871</DOCNO>
	<brief_summary>This open-label , randomize , parallel-arm study assess early immunologic response treatment-na√Øve Asian male patient chronic hepatitis B initiation treatment Pegasys tenofovir Pegasys plus tenofovir . Patients randomize one 4 cohort receive either Pegasys ( 360mcg subcutaneously weekly ) tenofovir ( 300mg orally daily ) treatment 2 week . After 2 week study treatment , patient may opt receive standard care treatment Pegasys . Target sample size &lt; 50 .</brief_summary>
	<brief_title>A Study Early Immunologic Response Asian Patients With Chronic Hepatitis B , Treated With Pegasys ( Peginterferon Alfa-2a ( 40KD ) ) , Nucleoside Analogues , Both</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>male adult Southeast and/or East Asian origin , 1855 year age HBeAgpositive chronic hepatitis B detectable HBV DNA prior antiviral therapy chronic hepatitis B evidence bridge fibrosis , cirrhosis decompensated liver disease positive test screening HAV ( IgM ) , HCV , HDV HIV history evidence medical condition associate chronic liver disease antineoplastic immunomodulatory treatment &lt; /=6 month prior first dose study drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>